The Complement-based Drug Development Summit will provide a comprehensive, end-to-end analysis of the research and development process in this space, spanning pre-clinical and clinical trial design through to gaining regulatory approval and upscaling manufacturing process to meet market demand.
The industry-dedicated meeting will provide an unparalleled opportunity for world leaders to share unique insights in the complement therapeutics space and collaborate to overcome barriers in drug development. Companies already participating include:
Alexion – Ra Pharma – Apellis – Bioverativ – GSK – Alnylam – Achillion – Novartis – ChemoCentryx – Annexon – Genentech – Regeneron – CSL Behring – Ionis – InflaRx – Ophthotech – Exsera Biolabs – Hemera Biosciences – Quidel – National Jewish Health – Charles River Laboratories – BioCryst – Comptech – Gemini Therapeutics – Kira – University of Colorado Denver – University of Lubeck – University of Amsterdam – Medical University of South Carolina
Join the foremost experts in complement therapeutics to examine the pathophysiology of disease through the relationships between pathway sub components, and how this can be leveraged to treat individual conditions and drive real change in drug development.